Insmed (INSM) Upgraded at BidaskClub

BidaskClub upgraded shares of Insmed (NASDAQ:INSM) from a sell rating to a hold rating in a report released on Saturday.

INSM has been the subject of a number of other reports. Zacks Investment Research lowered Insmed from a buy rating to a hold rating in a research report on Thursday, January 18th. Credit Suisse Group initiated coverage on Insmed in a research report on Wednesday, January 17th. They issued a neutral rating and a $31.00 price target for the company. ValuEngine upgraded Insmed from a sell rating to a hold rating in a research report on Friday, February 2nd. HC Wainwright restated a buy rating and issued a $35.00 price target on shares of Insmed in a research report on Thursday, January 4th. Finally, Robert W. Baird restated a positive rating and issued a $42.00 price target (up from $32.00) on shares of Insmed in a research report on Thursday, January 4th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and six have given a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and an average target price of $36.67.

How to Become a New Pot Stock Millionaire

Shares of Insmed (INSM) opened at $25.41 on Friday. The company has a current ratio of 8.72, a quick ratio of 8.72 and a debt-to-equity ratio of 0.15. The company has a market capitalization of $1,950.00, a P/E ratio of -8.85 and a beta of 1.13. Insmed has a 52 week low of $11.49 and a 52 week high of $33.94.

Insmed (NASDAQ:INSM) last posted its quarterly earnings results on Friday, February 23rd. The biopharmaceutical company reported ($0.85) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.18). equities analysts anticipate that Insmed will post -3.65 earnings per share for the current year.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Pictet Asset Management Ltd. lifted its holdings in Insmed by 5.6% in the third quarter. Pictet Asset Management Ltd. now owns 138,543 shares of the biopharmaceutical company’s stock valued at $4,324,000 after acquiring an additional 7,400 shares during the last quarter. Nationwide Fund Advisors lifted its holdings in Insmed by 20.2% in the third quarter. Nationwide Fund Advisors now owns 41,302 shares of the biopharmaceutical company’s stock valued at $1,289,000 after acquiring an additional 6,947 shares during the last quarter. Campbell & CO Investment Adviser LLC acquired a new position in Insmed in the third quarter valued at approximately $256,000. Schwab Charles Investment Management Inc. lifted its holdings in Insmed by 23.5% in the third quarter. Schwab Charles Investment Management Inc. now owns 347,798 shares of the biopharmaceutical company’s stock valued at $10,855,000 after acquiring an additional 66,148 shares during the last quarter. Finally, Alyeska Investment Group L.P. acquired a new position in Insmed in the third quarter valued at approximately $9,210,000. Hedge funds and other institutional investors own 99.10% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Insmed (INSM) Upgraded at BidaskClub” was first reported by Markets Daily and is the property of of Markets Daily. If you are accessing this piece of content on another website, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be viewed at https://www.themarketsdaily.com/2018/03/14/insmed-insm-upgraded-at-bidaskclub.html.

About Insmed

Insmed Incorporated is a biopharmaceutical company. The Company operates through development and commercialization of therapies for patients with rare diseases segment. Its lead product candidate is ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC).

Analyst Recommendations for Insmed (NASDAQ:INSM)

Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply